Zim Laboratories Ltd

Zim Laboratories Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Zim Laboratories Ltd

₹ 105 1.62%
22 Nov - close price
zimlab.in BSE: 541400 NSE: ZIMLAB
About

Incorporated in 1989, Zim Laboratories
Ltd manufactures formulation drugs and
pre formulation ingredients in India and
markets and sells these within and out
side India[1]

Key Points

Business Overview:[1]
ZLL is a EU-GMP, WHOGMP, NSF/ANSI 455-2 certified research-driven pharmaceutical company that develops, manufactures and supplies generic products in the oral solid dosage forms, both as pre-formulation intermediates ad finished formulations for certain key therapeutic segments. It offers both pharmaceutical and nutraceutical products.‍ Company has an in-house R&D capabilities to offer a range of non-infringing drug
delivery solutions based on process technologies

Website BSE NSE
  • Market Cap ₹ 510 Cr.
  • Current Price ₹ 105
  • High / Low ₹ 131 / 89.5
  • Stock P/E 31.6
  • Book Value ₹ 49.8
  • Dividend Yield 0.00 %
  • ROCE 9.98 %
  • ROE 7.86 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 1.84% over past five years.
  • Promoter holding is low: 33.3%
  • Company has a low return on equity of 9.77% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
77.47 86.72 105.06 92.75 99.40 100.97 105.41 67.44 85.83 96.29 117.86 81.82 92.14
67.20 76.04 90.31 81.56 87.14 87.87 89.96 62.62 76.50 84.75 102.21 73.78 82.61
Operating Profit 10.27 10.68 14.75 11.19 12.26 13.10 15.45 4.82 9.33 11.54 15.65 8.04 9.53
OPM % 13.26% 12.32% 14.04% 12.06% 12.33% 12.97% 14.66% 7.15% 10.87% 11.98% 13.28% 9.83% 10.34%
0.87 0.68 1.63 1.89 1.42 2.40 0.69 1.12 1.42 1.11 1.53 1.00 1.32
Interest 2.58 1.75 1.43 1.33 1.36 1.62 1.27 1.73 1.22 1.70 2.28 2.86 2.89
Depreciation 4.36 3.83 4.18 4.27 4.37 3.90 4.93 4.03 4.09 3.94 3.91 4.94 5.00
Profit before tax 4.20 5.78 10.77 7.48 7.95 9.98 9.94 0.18 5.44 7.01 10.99 1.24 2.96
Tax % 22.38% 29.76% 34.73% 31.15% 31.45% 33.87% 27.16% -22.22% 23.71% 31.81% 26.48% 27.42% 19.59%
3.26 4.07 7.03 5.15 5.45 6.60 7.24 0.23 4.15 4.78 8.09 0.90 2.38
EPS in Rs 0.67 0.84 1.44 1.06 1.12 1.35 1.49 0.05 0.85 0.98 1.66 0.18 0.49
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
266 269 235 273 335 278 307 333 399 367 388
278 239 203 238 293 255 268 292 347 326 343
Operating Profit -12 30 32 35 42 23 40 41 52 41 45
OPM % -4% 11% 13% 13% 13% 8% 13% 12% 13% 11% 12%
2 -2 5 9 2 5 -3 4 6 5 5
Interest 10 14 10 9 11 13 11 8 6 7 10
Depreciation 7 9 9 10 11 14 16 16 17 16 18
Profit before tax -27 5 18 25 22 0 10 21 35 24 22
Tax % -19% 5% -6% 23% 30% -4,600% 28% 31% 31% 27%
-22 5 19 19 15 3 7 15 24 17 16
EPS in Rs 3.17 0.68 1.50 2.99 5.01 3.54 3.31
Dividend Payout % 0% 16% 4% 4% 5% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 2%
3 Years: 6%
TTM: 8%
Compounded Profit Growth
10 Years: %
5 Years: 2%
3 Years: 16%
TTM: -11%
Stock Price CAGR
10 Years: %
5 Years: 31%
3 Years: 37%
1 Year: -10%
Return on Equity
10 Years: %
5 Years: 8%
3 Years: 10%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 8 8 8 8 16 16 16 16 49 49 49
Reserves 86 91 110 129 135 138 145 159 152 190 194
93 96 81 81 77 90 82 53 62 112 101
78 61 60 81 100 82 82 112 79 96 84
Total Liabilities 265 256 259 298 328 325 325 342 342 447 427
87 92 89 94 106 116 107 106 109 161 193
CWIP 6 3 4 8 13 10 11 12 27 42 33
Investments 0 0 0 0 0 0 0 0 0 0 0
172 161 166 196 209 200 208 224 206 244 201
Total Assets 265 256 259 298 328 325 325 342 342 447 427

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
22 32 37 35 22 32 49 38 16
-12 -7 -26 -21 -19 -6 -14 -36 -73
-10 -25 -10 -15 -2 -26 -33 1 60
Net Cash Flow -0 -0 1 -1 1 -0 2 3 3

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 111 120 137 119 101 89 86 98 87 100
Inventory Days 93 87 108 134 126 144 125 171 99 173
Days Payable 129 109 137 172 165 168 149 185 107 133
Cash Conversion Cycle 75 99 108 81 63 65 62 85 79 140
Working Capital Days 108 111 127 104 83 111 121 104 100 130
ROCE % 13% 14% 14% 15% 5% 11% 12% 17% 10%

Shareholding Pattern

Numbers in percentages

2 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.06% 0.00% 0.00% 0.01% 0.00% 0.00%
66.74% 66.74% 66.74% 66.75% 66.73% 66.74% 66.69% 66.75% 66.74% 66.74% 66.74% 66.73%
No. of Shareholders 3,6463,5613,5693,6436,0275,8798,98215,30517,34217,10017,48317,716

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls